Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody,
in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H)
advanced solid cancers.